Form 4: Pliant Therapeutics Director Receives Stock Option Grant

Director Gayle A. Crowell was granted 70,000 stock options in Pliant Therapeutics, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Gayle A. Crowell received a grant of 70,000 stock options for Pliant Therapeutics (PLRX) common stock.
• The options have an exercise price of $1.14 per share.
• The grant date is June 11, 2026, with an expiration date of June 11, 2036.
• Vesting occurs in quarterly installments starting October 1, 2026, through the one-year anniversary of the grant or the next annual meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment as it does not signal a change in company strategy or financial performance.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $1.14 exercise price.

Future Outlook

The options vest over a one-year period, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, though the specific exercise price reflects the current market valuation of the issuer.

Comparison to Industry Standards

• The vesting schedule of one year is relatively aggressive compared to the typical three-to-four-year vesting schedules seen in broader corporate governance standards.
• Equity-based compensation for directors is consistent with standard practices for mid-cap and small-cap biotech firms.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of 25% of options on October 1, 2026.
• Vesting of 25% of options on January 1, 2027.
• Vesting of 25% of options on April 1, 2027.
• Final vesting of remaining 25% on June 11, 2027 or the next annual meeting.

Key Dates

Keywords

PLRX, Pliant Therapeutics, Form 4, Insider Trading, Stock Options, Director Compensation